Cancer Therapy Advisor Staff

Researchers are conducting a phase 2 trial to test pembrolizumab and tamoxifen, with or without vorinostat, in patients with ER+ breast cancer.

Researchers are testing valemetostat plus trastuzumab deruxtecan in patients with HER2-low/ultra-low/null metastatic breast cancer.

Researchers are conducting a phase 1b/2 trial to test tucatinib plus alpelisib in patients with advanced, PIK3CA-mutant, HER2+ breast cancer.

Researchers are conducting a phase 1 trial to test CAR T-cell therapy in patients with mesothelin-expressing triple-negative breast cancer.

There are “minimal prognostic differences” between HER2-low breast cancer and HER2-negative breast cancer, according to researchers.

Researchers are conducting a phase 2 trial to test onapristone in combination with fulvestrant in patients with ER+, HER2- advanced breast cancer.

Researchers are conducting a phase 2 trial to test combination tucatinib, trastuzumab, and eribulin in patients with unresectable, locally advanced or metastatic HER2+ breast cancer.

Researchers are conducting a phase 1 trial to test AC699 in patients with ER+, HER2- locally advanced or metastatic breast cancer.

Researchers are conducting a phase 1b/2 study to test the safety and efficacy of niraparib plus trastuzumab in metastatic HER2+ breast cancer.

Researchers are conducting a phase 1b/2 study to test elacestrant plus onapristone in patients with HR+, HER2- advanced breast cancer.